- Johnson & Johnson has entered into a strategic deal with Sail Biomedicines to advance in vivo CAR-T therapies for immune-mediated diseases, which includes an option to acquire Sail for $2.58 billion.
- The transaction involves an initial payment of $785 million from Johnson & Johnson, including a $465 million equity investment.
- Separately, Johnson & Johnson is entering the robotic surgery market years after its competitors, betting that a unique approach will allow it to compete successfully.
Quotes
“Johnson & Johnson entered the fast-growing robotic surgery race years behind its rivals, but it’s betting a different approach can still win.”
“strategic deal with Sail Biomedicines to advance in vivo CAR-T therapies for immune-mediated diseases, along with an option to acquire Sail for $2.58B”